Biologists identify promising drug for ALS treatment
University of Alberta scientists find a new application for an existing drug, with potential to slow progression of the devastating degenerative disease.
A new drug could significantly slow the progression of ALS, also known as Lou Gehrig’s disease, according to new research by University of Alberta biologists. Current treatments slow progression of the degenerative disease by only a few months, and these findings could revolutionize the treatment of patients suffering from ALS, extending and improving quality of life.
The drug, called telbivudine, targets a protein that misfolds and does not function correctly in patients with ALS. “SOD1 is a protein that is known to misfold and misbehave in most cases of patients with ALS,” explained Ted Allison, associate professor in the Department of Biological Sciences and co-author on the study. “We showed that telbivudine can greatly reduce the toxic properties of SOD1, including improving the health of the subject’s motor neurons and improving movement.”
The research team used computer simulations to identify drugs with the potential for targeting the SOD1 protein. From this shortlist, the scientists identified and tested the most likely candidates—including telbivudine—using animal models.
“ALS is not well-understood,” said lead author Michele DuVal, who recently completed the PhD portion of the Faculty of Medicine & Dentistry’sMD/PhD program under the supervision of Allison. “We don’t yet know exactly what goes wrong first in the motor neurons or how the misbehaving SOD1 causes toxicity. Because there is still much to learn about the disease, the ALS research community focuses on both understanding ALS and on developing promising therapies.”
The discovery of telbivudine as a potential treatment is particularly exciting because the drug is already in use for treating patients with hepatitis. “It is already proven safe to use in patients, and it has very good potential for repurposing to use in a new clinical setting against ALS,” said Allison.
Learn more: Biologists identify promising drug for ALS treatment
The Latest on: Lou Gehrig’s disease
[google_news title=”” keyword=”Lou Gehrig’s disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Lou Gehrig’s disease
- NHL News: Flames assistant GM Chris Snow on life supporton September 28, 2023 at 4:45 pm
Calgary Flames assistant general manager Chris Snow is on life support while organ donation is arranged, his wife confirmed Thursday morning. Snow was diagnosed four years ago with amyotrophic lateral sclerosis,
- Lou Gehrig’s treatment loses voteon September 28, 2023 at 4:02 pm
Federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig’s disease at a Wednesday meeting prompted by years of patient efforts seeking access to the unproven therapy.
- A mistake may have cost seniors thousands in healthcare costs. N.J. is fixing it.on September 28, 2023 at 8:06 am
To qualify for free coverage, you need to have worked 40 quarters, or 10 years’ worth, of covered employment, or qualify through a spouse’s work history. Some others with disabilities, End-Stage Renal Disease (ESRD) or ALS — also called Lou Gehrig’s disease — are also eligible.
- Lou Gehrig's Diseaseon September 27, 2023 at 6:45 pm
Federal health advisors voted 17-1 against an experimental treatment for Lou Gehrig's disease dubbed NurOwn, although the FDA is not bound by the vote.
- Weekend walk highlights hope against 'mankind’s cruelest disease'on September 27, 2023 at 5:04 pm
The Team Hope Walk this weekend in Bloomington will raise money and awareness about Huntington’s disease. It’s sometimes known as "mankind’s cruelest disease" and one of the walkers lived under its cloud for decades.
via Bing News
